Clusters of Multidrug-Resistant Mycobacterium tuberculosis Cases, Europe
Isabelle Devaux , Kristin Kremer, Herre Heersma, and Dick van Soolingen
Author affiliations: European Centre for Disease Prevention and Control, Stockholm, Sweden (I. Devaux); National Institute for Public Health and the Environment, Bilthoven, the Netherlands (K. Kremer, H. Heersma, D. Van Soolingen)
Figure 1. Description of MDR TB cases in Europe selected for data analysis, January 2003–July 2007. RFA does not include data from Germany and Lithuania. MDR TB, multidrug-resistant tuberculosis; SLD, second-line drug; DST, drug-susceptibility test; RFA, risk factor analysis. *Countries: Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Ireland, Israel, Lithuania, the Netherlands, Norway, Spain, Sweden, Switzerland, and the United Kingdom.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.